Sarepta plans for 2015 drug review

Share this article:
Sarepta plans for 2015 drug review
Sarepta plans for 2015 drug review

Sarepta Therapeutics announced Monday that it will move forward with an NDA filing for its rare-disease muscular dystrophy drug by the end of this year.

The Cambridge, MA, had a setback in November when the FDA told the company it needed more data before considering the Duchenne Muscular Dystrophy drug's risks and benefits. Among its objections were that the data excluded “both younger boys who cannot perform such a demanding test, and older boys who are no longer ambulatory.”

Sarepta said in a statement that FDA discussions between November 2013 and March 2014 have shaped how it will move forward, including initiating several new studies  which “will include a clinical trial with predefined efficacy endpoints for ambulatory patients between the ages of 7 and 16 years who can walk a minimum distance, and two additional clinical trials that will evaluate safety and biomarkers in DMD patients younger than 7 years old.” Tests will also include patients who can no longer walk.

The drugmaker's announcement also includes a substantial amount of caution that goes beyond the typical “safe harbor” provisions that are attached to corporate projections. Sarepta is careful to note that FDA has stated that it “remains skeptical about the persuasiveness of the (dystrophin) data” and “is uncertain whether the existing dystorphin biomarker data will be persuasive enough to serve as a surrogate endpoint that is reasonably likely to predict clinical benefit.”

The FDA also urged Sarepta to begin confirmatory studies that show clinical benefit.

The rare disease is a genetic disorder that is expressed by low- or no production of the protein dystrophin. The Centers of Disease Control describes the protein as a glue that holds muscles together “by keeping the structure of muscle cells,” without which “muscles weaken over time and become unable to work properly.” The progressive disease generally effects more boys than girls and is diagnosed between the ages of 3 and 6. Most patients require wheelchairs by their early teens.

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...